Pharmacogenetics and irinotecan therapy-Reference-Cited by-同舟云学术

Pharmacogenetics and irinotecan therapy

Published:2006-11-15 Issue:22 Volume:63 Page:2211-2217
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

Hahn Kristine K.¹,Wolff James J.²,Kolesar Jill M.³

Affiliation:

1. University of Wisconsin Comprehensive Cancer Center (UWCCC), Madison

2. School of Pharmacy, University of Wisconsin (UW), Madison

3. Analytical Instrumentation Laboratory for Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics, UWCCC, and Associate Professor of Pharmacy, School of Pharmacy, UW

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/63/22/2211/28329728/ajhp2211.pdf

Reference40 articles.

1. Irinotecan Dosing: Does the CPT in CPT-11 Stand for “Can’t Predict Toxicity”?

2. Impact of Body-Size Measures on Irinotecan Clearance: Alternative Dosing Recommendations

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory Considerations in Metabolism‐ and Transport‐Based Drug Interactions;Oral Bioavailability and Drug Delivery;2023-10-10

2. Q&A of DMPK Issues and Tools for Drug Discovery;Discovery DMPK Quick Guide;2022

3. The “Chinese Expert Consensus on the Clinical Application of the Chinese Modified Triplet Combination with Irinotecan (CPT-11), Oxaliplatin (LOHP), Continuous Infusion 5-Fluorouracil, and Leucovorin for Colorectal Cancer”;Gastroenterology Report;2021-08-01

4. Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy;Process Biochemistry;2021-05

5. Molecular Mechanisms of Disease Resistance;Molecular Mechanism of Crucifer’s Host-Resistance;2021